Skip to main content

Table 2 Advantages of T2 mapping in selected myocardial diseases. The meta-analysis from Snel et al. included sufficient studies to conclude that T2 relaxation time is significantly prolonged above healthy subjects for all diseases included in this table except cardiac amyloidosis. Since the time of its publication, additional studies have shown T2 mapping as an accurate discriminator between AL and transthyretin amyloidosis as well as an accurate prognosticator (see Cardiac Amyloidosis section of main text). The rightmost column adds important advantages of T2 mapping

From: T2 mapping in myocardial disease: a comprehensive review

Disease Weighted mean T2 relaxation time at 1.5 T Number of studies in meta-analysis Clinical utility of T2 mapping
Myocardial infarction 58.5 ± 5.8 ms vs. 49.3 ± 2.6 ms in controls 31 T2 mapping differentiates acute vs. chronic myocardial infarction
T2 mapping is used in measuring area at risk
T2 mapping identifies intramyocardial hemorrhage
Heart transplant 54.6 ± 5.2 ms vs. 49.2 ± 2.5 in controls 11 T2 mapping is a reliable surrogate for direct tissue assessment in transplant rejection
Prolonged T2 time may identify patients that will benefit from immunosuppression modification despite negative endomyocardial biopsy
Myocarditis 61.9 ± 11.5 ms vs. 54.4 ± 5.9 ms in controls 19 Prolonged T2 time corresponds to myocardial edema and inflammation on biopsy
Abnormal T2 relaxation time has high sensitivity for diagnosing acute myocarditis
Persistently prolonged T2 relaxation time is associated with increased adverse cardiac events
Amyloidosis 55.3 ± 4.2 ms vs. 50.2 ± 2.7 in controls 2 Local toxicity of amyloid deposits results in longer T2 time, particularly in light chain (AL) amyloidosis
T2 mapping helps differentiate AL from ATTR amyloidosis
Dilated cardiomyopathy 62.9 ± 5.7 ms vs. 55.4 ± 3.5 in controls 9 T2 mapping improves early detection of dilated cardiomyopathy, prior to left ventricular dysfunction
Shorter T2 time in patients with successful reverse myocardial remodeling after goal directed medical therapy
  1. Data printed with permission from: Snel GJH, van den Boomen M, Hernandez LM, Nguyen CT, Sosnovik DE, Velthuis BK, Slart RHJA, Borra RJH, Prakken NHJ. Cardiovascular magnetic resonance native T2 and T2* quantitative values for cardiomyopathies and heart transplantations: a systematic review and meta-analysis. Journal of Cardiovascular Magnetic Resonance. 2020;22(1):34. https://doi.org/10.1186/s12968-020-00627-x